Antiresorptive therapies for osteoporosis: A clinical overview

Nature Reviews Endocrinology

Volumn 8, Issue 2, 2012, Pages 81-91

  Chen, Jian Sheng ^a   Sambrook, Philip N ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; CALCITONIN; CLODRONIC ACID; DENOSUMAB; ESTROGEN; ETIDRONIC ACID; GESTAGEN; GLUCOCORTICOID; IBANDRONIC ACID; LASOFOXIFENE; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ARTHRALGIA; BLEEDING; BONE STRENGTH; BREAST CANCER; CANCER INVASION; CELLULITIS; CREATININE BLOOD LEVEL; DERMATITIS; DRUG DOSE COMPARISON; ECZEMA; ERYTHEMA; ESOPHAGUS CANCER; FEMUR FRACTURE; FEVER; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ATRIUM FIBRILLATION; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; JAW OSTEONECROSIS; LEG CRAMP; LUNG EMBOLISM; META ANALYSIS (TOPIC); MYALGIA; NAUSEA; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT PREFERENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RHINITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN INFECTION; SNEEZING; STOMACH ULCER; STROKE; URINARY TRACT INFECTION; VENOUS THROMBOEMBOLISM;

ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84856505157     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.146     Document Type: Review

References (110)

1. Melton, L. J. III. How many women have osteoporosis now? J. Bone Miner. Res. 10, 175-177 (1995).
2. Vestergaard, P., Rejnmark, L. & Mosekilde, L. Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos. Int. 16, 134-141 (2005). (Pubitemid 40193199)
3. Johnell, O. & Kanis, J. A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 17, 1726-1733 (2006). (Pubitemid 44607392)
4. The prevention and management of osteoporosis consensus statement. The Medical Journal of Australia [online], http://www.mja.com.au/public/guides/ osteo/whatis.html (1997).
5. Cameron, I. D. et al. Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: a prospective 5-year study. J. Bone Miner. Res. 25, 866-872 (2010).
6. Center, J. R., Bliuc, D., Nguyen, T. V. & Eisman, J. A. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 297, 387-394 (2007). (Pubitemid 46155800)
7. Johnell, O. et al. Fracture risk following an osteoporotic fracture. Osteoporos. Int. 15, 175-179 (2004). (Pubitemid 38391531)
8. Chen, J. et al. Low-trauma fractures indicate increased risk of hip fracture in frail older people. J. Bone Miner. Res. 26, 428-433 (2010).
9. Chen, J. S., Hogan, C., Lyubomirsky, G. & Sambrook, P. N. Management of osteoporosis in primary care in Australia. Osteoporos. Int. 20, 491-496 (2009).
10. Kok, C. & Sambrook, P. N. Secondary osteoporosis in patients with an osteoporotic fracture. Best Pract. Res. Clin. Rheum. 23, 769-779 (2009).
11. Cummings, S. R. et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N. Engl. J. Med. 332, 767-773 (1995).
12. Huang, A. J. et al. Endogenous estrogen levels and the effects of ultra low dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women. J. Bone Miner. Res. 22, 1791-1797 (2007). (Pubitemid 351235146)
13. Rosen, C. J. Clinical practice. Postmenopausal osteoporosis. N. Engl. J. Med. 353, 595-603 (2005).
14. Black, D. M. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356, 1809-1822 (2007). (Pubitemid 46698462)
15. Ensrud, K. E. et al. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J. Bone Miner. Res. 23, 112-120 (2008).
16. Wells, G. A. et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD003376 doi:10.1002/14651858.CD003376. pub3 (2008). (Pubitemid 351807542)
17. Wells, G. A. et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD004523 doi:10.1002/14651858.CD004523. pub3 (2008). (Pubitemid 351824594)
18. Wells, G. A. et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD001155 doi:10.1002/14651858.CD001155. pub2 (2008). (Pubitemid 351807494)
19. Orwoll, E. et al. Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. 343, 604-610 (2000). (Pubitemid 30659471)
20. Ringe, J. D., Faber, H. & Dorst, A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J. Clin. Endocrinol. Metab. 86, 5252-5255 (2001). (Pubitemid 33070244)
21. Sato, Y., Iwamoto, J., Kanoko, T. & Satoh, K. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch. Intern. Med. 165, 1743-1748 (2005). (Pubitemid 41138962)
22. Taylor, J. C. et al. Opinions and experiences in general practice on osteoporosis prevention, diagnosis and management. Osteoporos. Int. 12, 844-848 (2001). (Pubitemid 33086271)
23. Jaglal, S. B. et al. How are family physicians managing osteoporosis? Qualitative study of their experiences and educational needs. Can. Fam. Physician 49, 462-468 (2003). (Pubitemid 36700652)
24. Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002). (Pubitemid 34761611)
25. Recker, R. R. et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J. Bone Miner. Res. 24, 1358-1368 (2009).
26. Hosking, D. et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N. Engl. J. Med. 338, 485-492 (1998). (Pubitemid 28103131)
27. Siris, E. S. et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J. Bone Miner. Res. 20, 1514-1524 (2005). (Pubitemid 41243540)
28. Cummings, S. R. et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am. J. Med. 112, 281-289 (2002). (Pubitemid 34219441)
29. Russell, R. G., Watts, N. B., Ebetino, F. H. & Rogers, M. J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 19, 733-759 (2008).
30. Vestergaard, P., Mosekilde, L. & Langdahl, B. Fracture prevention in postmenopausal women. Clin. Evid. (Online) 2011, pii: 1109 (2011).
31. Rahmani, P. & Morin, S. Prevention of osteoporosis-related fractures among postmenopausal women and older men. CMAJ 181, 815-820 (2009).
32. Chesnut, C. H. III. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. 19, 1241-1249 (2004). (Pubitemid 41094364)
33. Cranney, A. et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos. Int. 20, 291-297 (2009).
34. McCloskey, E. et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J. Bone Miner. Res. 19, 728-736 (2004). (Pubitemid 41094383)
35. McCloskey, E. V. et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J. Bone Miner. Res. 22, 135-141 (2007). (Pubitemid 46032606)
36. Green, J. et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 341, c4444 (2010).
37. Khosla, S. et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral. Research. J. Bone Miner. Res. 22, 1479-1491 (2007). (Pubitemid 351229318)
38. Cartsos, V. M., Zhu, S. & Zavras, A. I. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J. Am. Dent. Assoc. 139, 23-30 (2008).
39. Bhuriya, R., Singh, M., Molnar, J., Arora, R. & Khosla, S. Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Int. J. Cardiol. 142, 213-217 (2010).
40. Mak, A., Cheung, M. W., Ho, R. C., Cheak, A. A. & Lau, C. S. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet. Disord. 10, 113 (2009).
41. Bisphosphonates marketed as Alendronate (Fosamax, Fosamax Plus D), Etidronate (Didronel), Ibandronate (Boniva), Pamidronate (Aredia), Risedronate (Actonel, Actonel W/Calcium), Tiludronate (Skelid), and Zoledronic acid (Reclast, Zometa). FDA [online], http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150837.htm (2007).
42. Odvina, C. V. et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90, 1294-1301 (2005). (Pubitemid 40463979)
43. Lenart, B. A., Lorich, D. G. & Lane, J. M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N. Engl. J. Med. 358, 1304-1306 (2008). (Pubitemid 351439247)
44. Abrahamsen, B., Eiken, P. & Eastell, R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J. Bone Miner. Res. 24, 1095-1102 (2009).
45. Shane, E. et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 25, 2267-2294 (2010).
46. Cardwell, C. R., Abnet, C. C., Cantwell, M. M. & Murray, L. J. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304, 657-663 (2010).
47. Papapetrou, P. D. Bisphosphonate-associated adverse events. Hormones (Athens) 8, 96-110 (2009).
48. Lyles, K. W. et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 357, 1799-1809 (2007). (Pubitemid 350044800)
49. Colon-Emeric, C. S. et al.. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J. Bone Miner. Res. 25, 91-97 (2010).
50. Center, J. R., Bliuc, D., Nguyen, N. D., Nguyen, T. V. & Eisman, J. A. Osteoporosis medication and reduced mortality risk in elderly women and men. J. Clin. Endocrinol. Metab. 96, 1006-1014 (2011).
51. Sambrook, P. N. et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos. Int. 22, 2551-2556 (2011).
52. Bolland, M. J., Grey, A. B., Gamble, G. D. & Reid, I. R. Effect of osteoporosis treatment on mortality: a meta-analysis. J. Clin. Endocrinol. Metab. 95, 1174-1181 (2010).
53. Anderson, G. L. et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291, 1701-1712 (2004). (Pubitemid 38489892)
54. Torgerson, D. J. & Bell-Syer, S. E. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 285, 2891-2897 (2001). (Pubitemid 32537354)
55. Torgerson, D. J. & Bell-Syer, S. E. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomized trials. BMC Musculoskelet. Disord. 2, 7 (2001).
56. Lindsay, R., Gallagher, J. C., Kleerekoper, M. & Pickar, J. H. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos. Int. 16, 372-379 (2005). (Pubitemid 40487394)
57. Barrett-Connor, E. et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355, 125-137 (2006). (Pubitemid 44050394)
58. Delmas, P. D. et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab. 87, 3609-3617 (2002). (Pubitemid 34879503)
59. Adomaityte, J., Farooq, M. & Qayyum, R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb. Haemost. 99, 338-342 (2008). (Pubitemid 351230964)
60. Cranney, A. et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr. Rev. 23, 524-528 (2002). (Pubitemid 34925646)
61. Cummings, S. R. et al. Lasofoxifene in postmenopausal women with osteoporosis. N. Engl. J. Med. 362, 686-696 (2010).
62. Silverman, S. L. et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J. Bone Miner. Res. 23, 1923-1934 (2008).
63. Silverman, S. L. New selective estrogen receptor modulators (SERMs) in development. Curr. Osteoporos. Rep. 8, 151-153 (2010).
64. Chesnut, C. H. III. et al. Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos. Int. 19, 479-491 (2008).
65. Silverman, S. L. & Azria, M. The analgesic role of calcitonin following osteoporotic fracture. Osteoporos. Int. 13, 858-867 (2002). (Pubitemid 35364786)
66. Chesnut, C. H. III. et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am. J. Med. 109, 267-276 (2000).
67. Cranney, A. et al. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr. Rev. 23, 540-551 (2002). (Pubitemid 34925648)
68. Miller, P. D. et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43, 222-229 (2008).
69. Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756-765 (2009).
70. ProliaTM (denosumab) prescribing information. Amgen Inc. [online], http://pi.amgen.com/united-states/prolia/prolia-pi.pdf (2010).
71. Center, J. R., Nguyen, T. V., Schneider, D., Sambrook, P. N. & Eisman, J. A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353, 878-882 (1999). (Pubitemid 29126875)
72. Johnell, O., Kanis, J. & Gullberg, G. Mortality, morbidity, and assessment of fracture risk in male osteoporosis. Calcif. Tissue Int. 69, 182-184 (2001). (Pubitemid 33035382)
73. Baillie, S. P., Davison, C. E., Johnson, F. J. & Francis, R. M. Pathogenesis of vertebral crush fractures in men. Age Ageing 21, 139-141 (1992).
74. Ringe, J. D., Dorst, A., Faber, H. & Ibach, K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol. Int. 24, 110-113 (2004). (Pubitemid 38388755)
75. Ringe, J. D., Faber, H., Farahmand, P. & Dorst, A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol. Int. 26, 427-431 (2006).
76. Smith, M. R. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745-755 (2009).
77. Sato, Y., Honda, Y. & Iwamoto, J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 68, 911-915 (2007). (Pubitemid 46568502)
78. Boonen, S. et al. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J. Bone Miner. Res. 24, 719-725 (2009).
79. Saad, F. et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94, 1458-1468 (2002).
80. Toth, E. et al. The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures-an open label study. Bone 36, 47-51 (2005). (Pubitemid 40128273)
81. Snyder, P. J. et al. Effects of testosterone replacement in hypogonadal men. J. Clin. Endocrinol. Metab. 85, 2670-2677 (2000). (Pubitemid 32269134)
82. Van Staa, T. P., Leufkens, H. G. & Cooper, C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. 13, 777-787 (2002). (Pubitemid 36336722)
83. Angeli, A. et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39, 253-259 (2006). (Pubitemid 43870263)
84. Naganathan, V. et al. Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch. Intern. Med. 160, 2917-2922 (2000). (Pubitemid 32009048)
85. Homik, J. E. et al. A meta-analysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J. Rheumatol. 26, 1148-1157 (1999). (Pubitemid 29215082)
86. Cranney, A. et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database of Systematic Reviews Issue 1. Art. No.: CD001983 doi:10.1002/14651858.CD001983 (2000).
87. Dawson-Hughes, B. & National Osteoporosis Foundation Guide Committee. A revised clinician's guide to the prevention and treatment of osteoporosis. J. Clin. Endocrinol. Metab. 93, 2463-2465 (2008). (Pubitemid 352008504)
88. Kanis, J. A. et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 19, 399-428 (2008).
89. Fracture Risk Calculator. Garvan Institute [online], http://www.garvan. org.au/bone-fracture-risk/ (2011).
90. Kanis, J. A., Johnell, O., Oden, A., Johansson, H. & McCloskey, E. FRAX and the assessment of fracture probability in men and women from the U. K. Osteoporos. Int. 19, 385-397 (2008).
91. Utian, W. H. et al.. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of the North American Menopause Society. Menopause 15, 584-602 (2008).
92. Bauer, D. C. et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J. Bone Miner. Res. 19, 1250-1258 (2004). (Pubitemid 41094365)
93. Seibel, M. J., Naganathan, V., Barton, I. & Grauer, A. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J. Bone Miner. Res. 19, 323-329 (2004). (Pubitemid 38116747)
94. Bone, H. G. et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350, 1189-1199 (2004). (Pubitemid 38339363)
95. Black, D. M. et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296, 2927-2938 (2006). (Pubitemid 46021497)
96. Schwartz, A. V. et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J. Bone Miner. Res. 25, 976-982 (2010).
97. Cramer, J. A., Gold, D. T., Silverman, S. L. & Lewiecki, E. M. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos. Int. 18, 1023-1031 (2007). (Pubitemid 47019996)
98. Kamatari, M. et al. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J. Bone Miner. Metab. 25, 302-309 (2007). (Pubitemid 47283269)
99. Rossini, M. et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos. Int. 17, 914-921 (2006). (Pubitemid 43781506)
100. Landfeldt, E., Strom, O., Robbins, S. & Borgstrom, F. Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA). Osteoporos. Int. doi:10.1007/s00198-011- 1549-6.
101. Downey, T. W., Foltz, S. H., Boccuzzi, S. J., Omar, M. A. & Kahler, K. H. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med. J. 99, 570-575 (2006). (Pubitemid 43999919)
102. Saag, K. G. et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 339, 292-299 (1998). (Pubitemid 28366417)
103. Adachi, J. D. et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 44, 202-211 (2001). (Pubitemid 32113136)
104. Cohen, S. et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 42, 2309-2318 (1999). (Pubitemid 30333410)
105. Wallach, S. et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 67, 277-285 (2000).
106. Adachi, J. D. et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. 337, 382-387 (1997). (Pubitemid 27328368)
107. Sato, S. et al. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year follow-up. J. Rheumatol. 30, 2673-2679 (2003). (Pubitemid 37549348)
108. Campbell, I. A. et al. Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax 59, 761-768 (2004). (Pubitemid 39215372)
109. Reid, D. M. et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomized controlled trial. Lancet 373, 1253-1263 (2009).
110. Dore, R. K. et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann. Rheum. Dis. 69, 872-875 (2010).